LBA-07 Updated Results of the MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E mutated (BRAFm) metastatic colorectal cancer (mCRC)

Eric Van Cutsem, Ryan B. Corcoran, Robin M.J.M. van Geel et al.|Annals of Oncology|2015

Cited by 23